Drug Trial Radar · NCT03522298
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Last checked: Nov 19, 2026Latest source record: Mar 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
May 15, 2018
Primary completion
Mar 30, 2023
Study completion Mar 30, 2023
Sponsor
- Lead sponsor
- Kazia Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol has a 2-part design: This phase 2 study is an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics (PK) and clinical activity of paxalisib in patients with newly-diagnosed glioblastoma (GBM) with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with temozolomide (TMZ).
Conditions
- Glioblastoma, Adult
Interventions
Paxalisib (GDC-0084)Drug
Patients will be dosed orally with paxalisib (GDC-0084) capsules (15-mg each) at the dose and schedule to which they are assigned.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Time frame: Cycle 1, Days 1-28
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles - Jonsson Comprehensive Cancer Center
Los Angeles, California
University of Colorado Cancer Center
Aurora, Colorado
Dana Farber Cancer Institute
Boston, Massachusetts
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
University of Oklahoma Health Sciences Center (Stephenson Cancer Center)
Oklahoma City, Oklahoma
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.